Generic Name and Formulations:
Thioguanine 40mg; tabs; scored.
Indications for TABLOID:
Remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. Treatment of the chronic phase of chronic myelogenous leukemia (see literature).
Adults and Children:
See literature. Initially, 2mg/kg per day. If, after 4 weeks, with no improvement, no leukocyte or platelet depression, may increase to 3mg/kg per day. Total daily dose may be given at one time.
Allergy to mercaptopurine.
Not recommended for maintenance therapy or long-term continuous treatments; increased risk of liver toxicity (discontinue if occurs). Pre-existing liver disease. Monitor liver function tests weekly at start of therapy, then monthly thereafter. Thiopurine methyltransferase (TPMT) enzyme deficiency (may need to reduce dose to avoid severe bone marrow suppression); consider testing for TPMT deficiency. Obtain hemoglobin, hematocrit, WBCs with differential, platelets frequently during therapy. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Avoid live vaccines (if immunocompromised). Caution with drugs that inhibit TPMT (eg, olsalazine, mesalazine, or sulphasalazine).
Myelosuppression, hyperuricemia, GI upset, anorexia, stomatitis, hepatotoxicity, elevated liver enzymes, jaundice (discontinue if occurs).
Endocrinology Advisor Articles
- Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- ADA Issues White Paper Addressing Escalating Cost of Insulin
- Neprilysin Inhibition May Reduce Renal Function Deterioration in Comorbid T2D and Chronic Heart Failure
- Serum Chemerin May Predict Risk for Spontaneous Abortion in Women With PCOS
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Effects of Gender on Clinical Outcomes in Empagliflozin-Treated Type 2 Diabetes
- Effect of Acetyl-L-Carnitine on Blood Pressure in Type 2 Diabetes
- PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones
- Perioperative Cardiovascular Events More Common in Diabetes
- Individuals With Type 1 Diabetes See Improvement With Continuous Glucose Monitoring